Criteo S.A. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Criteo S.A. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.30B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $1.80B | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $1.32B | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $988.25M | Mar 1, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.94B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.93B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.95B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.02B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $2.25B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $2.07B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $2.26B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $2.30B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $2.30B | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $1.80B | Mar 1, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.05B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $982.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $863.04M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $795.20M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $781.94M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $688.02M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $829.04M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $834.24M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $819.50M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $644.98M | Mar 1, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $144.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $111.57M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $53.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $8.95M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $134.46M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $71.68M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $90.75M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $88.64M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $91.21M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $82.27M | Mar 1, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.77M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $151.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $77.22M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $24.28M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $151.88M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $108.83M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $141.21M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $147.11M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $137.84M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $121.00M | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $283.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $279.34M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $242.29M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $187.60M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $151.82M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $132.51M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $172.59M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $179.26M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $173.93M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $123.65M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $311.24M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $258.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $224.25M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $255.99M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $220.91M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $185.36M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $222.83M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $260.73M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $245.46M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $153.47M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.27B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.39B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.35B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.98B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.85B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.79B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.60B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.53B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.21B | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.19B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.28B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.27B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $785.27M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $700.72M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $752.40M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $629.24M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $633.60M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $601.31M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.05B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.08B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.05B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.16B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.12B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.01B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $943.67M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $881.53M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $600.13M | Mar 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $535.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $515.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $524.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $515.14M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $329.70M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $325.81M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $317.10M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $312.88M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $236.83M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $209.42M | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $630.75M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $571.74M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $555.46M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $577.65M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $601.59M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $491.36M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $451.73M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $387.87M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $300.21M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $198.36M | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $342.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $290.69M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $336.34M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $348.20M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $515.53M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $488.01M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $418.76M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $364.43M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $414.11M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $270.32M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $1.51M | Feb 26, 2021 |
| FY2019 | Dec 31, 2019 | $2.12M | Mar 2, 2020 |
| FY2018 | Dec 31, 2018 | $2.94M | Mar 1, 2019 |
| FY2017 | Dec 31, 2017 | $2.78M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $82.92M | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $9.25M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $13.05M | Mar 1, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Mar 1, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Mar 1, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.15M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 54.28M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 61.17M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 63.25M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 65.88M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 66.27M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 66.20M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 67.71M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | 66.09M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | 63.98M | Mar 1, 2019 |